| First Author | Xiong J | Year | 2022 |
| Journal | Nature | Volume | 603 |
| Issue | 7901 | Pages | 470-476 |
| PubMed ID | 35236988 | Mgi Jnum | J:338102 |
| Mgi Id | MGI:7294122 | Doi | 10.1038/s41586-022-04463-0 |
| Citation | Xiong J, et al. (2022) FSH blockade improves cognition in mice with Alzheimer's disease. Nature 603(7901):470-476 |
| abstractText | Alzheimer's disease has a higher incidence in older women, with a spike in cognitive decline that tracks with visceral adiposity, dysregulated energy homeostasis and bone loss during the menopausal transition(1,2). Inhibiting the action of follicle-stimulating hormone (FSH) reduces body fat, enhances thermogenesis, increases bone mass and lowers serum cholesterol in mice(3-7). Here we show that FSH acts directly on hippocampal and cortical neurons to accelerate amyloid-beta and Tau deposition and impair cognition in mice displaying features of Alzheimer's disease. Blocking FSH action in these mice abrogates the Alzheimer's disease-like phenotype by inhibiting the neuronal C/EBPbeta-delta-secretase pathway. These data not only suggest a causal role for rising serum FSH levels in the exaggerated Alzheimer's disease pathophysiology during menopause, but also reveal an opportunity for treating Alzheimer's disease, obesity, osteoporosis and dyslipidaemia with a single FSH-blocking agent. |
